Are you a practitioner?

Join our network
join us illustration
Medical Oncologist
Dr Evangelos Sarris Medical Oncologist: Book an online appointment

Sarris Evangelos MD, MSc

Medical Oncologist Ampelokipoi

10.0 | 9 reviews
Location

Mesogeion Avenue 107( Henry Dunant Hospital Center), Ampelokipoi, Attica

Next availability
Check availability

Why he is suitable for you

Evangelos Sarris is a Medical Oncologist and Director of the 6th Oncology Clinic at Henry Dunant Hospital Center. He graduated from the Medical School of the National and Kapodistrian University of Athens and holds a postgraduate degree in Thoracic Oncology from the same institution. He obtained his specialty certification in Medical Oncology in 2020, achieving an outstanding score of 96/100 in the specialist examinations. In 2024, he was selected to participate in the IASLC (International Association for the Study of Lung Cancer) Academy, alongside distinguished colleagues in the field of thoracic oncology from around the world. He has extensive clinical experience in oncology, having worked as a resident and subsequently as an attending physician at leading hospitals in Athens. His significant research contributions include numerous publications in international scientific journals, and he has participated as a speaker at numerous Greek and international oncology conferences. His clinical approach combines personalized medicine with the latest advances in clinical research, aiming to provide patients with access to innovative treatments and high-quality oncological care.

The description was edited by the doctoranytime team, based on verified information.

Availability

The specialist's availability depends on the service you select.

Mesogeion Avenue 107( Henry Dunant Hospital Center), Ampelokipoi, Attica

Next availability

Services

Costs are indicative and will be determined on a case by case basis

Patient Reviews

10.0
From 9 reviews

Real reviews for real people

Investigated my case in depth
10
Trustworthy
10
Experienced & qualified
10
Punctual
10
Approachable & friendly
9.9

Reviews are written by people who had an appointment with a specialist and want to share their experience. Learn how we ensure their authenticity

  • All (9)
  • Positive (9)
  • Neutral (0)
  • Negative (0)
9.8
Αντωνης • 8 reviews
Ένας πολύ καταρτισμένος ιατρός..πολύ αναλυτικός και ταυτόχρονα ανθρώπινος. Θα τον συνιστούσα.
07 March 2026
10.0
Αθηνά • 1 review
Άριστος επαγγελματίας, με γνώση και ενσυναίσθηση. Τον συνιστώ ανεπιφύλακτα.
13 December 2025
10.0
Valeria • 1 review
Εξαιρετικός γιατρός με υπομονή, αγάπη για τη δουλειά του και ανθρωπιά. Μπορώ να πω ότι κυριολεκτικά με την βοήθεια του έσωσε τον σύζυγό μου. Μετά από μια περιπέτεια 18 χρόνων με καρκίνο επιτέλους βρήκα έναν γιατρό που κάνει λειτούργημα και έχει πάθος και εξαιρετικές γνώσεις. Όλη η οικογένεια βρήκε γαλήνη και αισιοδοξία εξαιτίας του. Πότε δεν θα είναι αρκετό το ευχαριστώ που του χρωστάμε.
02 December 2025
10.0
Ilias • 1 review
Εξαιρετικός ιατρός με επιστημονική προσέγγιση και πάνω από όλα εξαιρετικός άνθρωπος!!
01 December 2025
10.0
Όλγα • 1 review
Εξαιρετικός γιατρός!! Άρτια καταρτισμένος και άψογος επαγγελματίας και πάνω απ'όλα άνθρωπος!!
01 December 2025
10.0
Χρυσα • 1 review
Επαγγελματίας υψηλού επιπέδου, με εντυπωσιακή επιστημονική κατάρτιση και πραγματική αγάπη για αυτό που κάνει.Τον συνιστώ ανεπιφύλακτα σε όποιον χρειάζεται έναν σπουδαίο ογκολόγο που συνδυάζει γνώση, εμπειρία και ανθρωπιά .
01 December 2025
10.0
ΧΑΡΗΣ • 1 review
Εξαιρετικός γιατρός! Ο κ. Βαγγέλης Σαρρής είναι ένας παθολόγος–ογκολόγος με βαθιά γνώση και υψηλό επαγγελματισμό. Είναι ευγενικός, προσεκτικός και πάντα πρόθυμος να απαντήσει σε κάθε απορία. Τον συστήνω ανεπιφύλακτα σε όποιον αναζητά έναν γιατρό με επιστημονική κατάρτιση αλλά και ανθρώπινη προσέγγιση.
01 December 2025
10.0
Elena • 1 review
Υπεροχος γιατρος και πανω απολα ανθρωπος!! Απολυτα καταρτισμενος και σου εμπνεει ασφαλεια!!!
01 December 2025
10.0
Ελένη • 1 review
Εξαιρετικός γιατρός που μας ενέπνευσε μεγάλη εμπιστοσύνη με την επιστημονική του κατάρτιση. Απάντησε σε όλες μας τις ερωτήσεις, έλυσε κάθε μας απορία και μας έκανε να νιώσουμε ασφάλεια για τη συνέχεια.
28 October 2025

Contact and location

    • Address
      Mesogeion Avenue 107( Henry Dunant Hospital Center), Ampelokipoi, Attica
    • Parking
      • No parking available
Could not find any practice in map.

Payment Methods

Select practice

  • Payment Methods

    • Bank Card
    • Pay with Klarna
    • Cash

    Appointment Policy

    • Payment Options

      You can select online payment during booking or pay for the appointment at the specialist's practice.

    • Cancellation

      You can always cancel up to 3 hours before the appointment. In case of online payment you will receive a refund. For more information please read our cancellation and refund policy.

    Insurances

    • Private appointment

Curriculum Vitae and Career

Studies

  • Participation in the Academy, IASLC (International Association for the Study of Lung Cancer) (2024)
  • Specialty Certification, Medical Oncology (2020)
  • Master’s Degree (MSc) in Thoracic Oncology, Medical School, National and Kapodistrian University of Athens (2015)
  • Medical Degree, National and Kapodistrian University of Athens (2009)

Professional experience

  • Medical Oncologist, Director of the 6th Oncology Clinic, Henry Dunant Hospital Center (2026 - Σήμερα)
  • Consultant Medical Oncologist, 4th Oncology Department and Model Clinical Trials Center, Metropolitan Hospital, Neo Faliro (2021 - Present)
  • Oncology Trainee, General Anti-Cancer – Oncology Hospital of Athens “Agios Savvas” (2017 - 2020)
  • Internal Medicine Trainee, General Hospital of Attica “Sismanoglio - Amalia Fleming” (2013 - 2017)
  • Scientific Collaborator, Oncology Unit, 3rd University Medical Department, General Hospital of Thoracic Diseases of Athens “Sotiria” (2012 - 2013)
  • Rural Service Physician, General Hospital of Karystos “Diokleion” – Health Center of Karystos (Evia) (2010 - 2011)

Organisations member

  • European Society for Medical Oncology (ESMO), Μέλος
  • International Association for the Study of Lung Cancer (IASLC), Μέλος
  • Hellenic Cooperative Oncology Group (HeCOG), Μέλος
  • Ελληνική Εταιρεία Παθολογικής Ογκολογίας (HeSMO), Μέλος
  • Ομάδα Νέων Ογκολόγων Ελλάδας (HeGYO), Μέλος

Spoken languages

  • English
  • German

Academic research and publications

  • Συμμετοχή στην συγγραφή των θεραπευτικών πρωτοκόλλων για τον καρκίνο του πνεύμονα της Εταιρείας Ογκολόγων - Παθολόγων Ελλάδας (Ε.Ο.Π.Ε.)
  • Συνερευνητής σε κλινικές και μεταφραστικές μελέτες του Hellenic Cooperative Oncology Group (HeCOG)
  • ΕΠΙΣΤΗΜΟΝΙΚΗ ΔΡΑΣΤΗΡΙΟΤΗΤΑ
  • Συμμετοχή ως ομιλητής σε πολυάριθμα Ελληνικά και διεθνή συνέδρια Ογκολογίας
  • Συμμετοχή στη συγγραφή των κλινικών εγχειριδίων: «Νέες Θεραπείες στην Ογκολογία: Εγχειρίδιο για τη Διαχείριση Ανεπιθύμητων Ενεργειών» «Νέες Θεραπείες στην Ογκολογία: Εγχειρίδιο Ενημέρωσης Ασθενών για τις Ανεπιθύμητες Ενέργειες» Επίσημες εκδόσεις της Ομάδας Νέων Ογκολόγων (HeGYO) και της Ελληνικής Εταιρείας Ογκολογίας (HeSMO), με ISBN από την Εθνική Βιβλιοθήκη, υπό την αιγίδα της HeSMO (2019)
  • Συμμετοχή στη συγγραφή του εγχειριδίου «Νέα Φάρμακα στην Ογκολογία», στο πλαίσιο του 6ου και 7ου Επιστημονικού Φόρουμ: «Νέα φάρμακα στην ογκολογία: από την έρευνα στην πράξη», 2018–2019
  • ΑΚΑΔΗΜΑΙΚΕΣ ΔΗΜΟΣΙΕΥΣΕΙΣ
  • Sarris E, Saif M, Syrigos K. The Biological Role of PI3K Pathway in Lung Cancer. Pharmaceuticals (Basel). 2012 Nov 20;5(11):1236-64
  • Sarris E, Syrigos K, Saif M. Pancreatic cancer: updates on translational research and future applications. JOP. 2013 Mar 10;14(2):145-8.
  • Sarris E, Syrigos K, Saif M. Novel agents and future prospects in the treatment of pancreatic adenocarcinoma. JOP. 2013 Jul 10;14(4):395-400.
  • Sarris E, Harrington K, Saif M, Syrigos K. Multimodal treatment strategies for elderly patients with head and neck cancer. Cancer Treat Rev. 2014 Apr;40(3):465-75.
  • Sarris E, Tsimpoukis S, Karampelas I, Syrigos K. Prolongation of PFS and OS in patients with lung adenocarcinoma after treatment with bevacizumab beyond progression. Book: Bevacizumab in Lung Cancer: Impact and Exceptional Cases.
  • Sarris E, Linardou H, Kosmidis T, Papadopoulou K, Korfiatis N, Gouedard C, Vozikis A, Lampaki S, Psyrri A, Fountzila E, Christopoulou A, Samantas E, Vagionas A, Mountzios G, Goumas G, Tsoukalas N, Athanasiadis I, Bafaloukos D, Panopoulos C, Koufaki M.I, Fountzilas G, Kosmidis P. SNF-CLIMEDIN: A Prospective Randomized Trial of Digital Intervention in Patients with Advanced NSCLC. A HECOG STUDY. Forum of Clinical Oncology, Volume 15 (2024): Issue 2, December 2024.
  • Syrigos K, Sarris E, Strimpakos A. Erlotinib (E) in non-small cell lung cancer (NSCLC) patients (pts) ≥75 years old with comorbidities (cM): Experience at a tertiary referral center. J Clin Oncol 31, 2013 (suppl; abstr e19111).
  • Strimpakos A, Sarris E, Syrigos K. Pharmaceutical agents used for the treatment of cancer cachexia. Forum of Clinical Oncology 3(3):50-57, January 2012.
  • Syrigos K, Sarris E, Kotteas I, et al. TTF-1 Expression as a Predictor of Response to EGFR-TKIs in Patients with Lung Adenocarcinoma. Journal of Thoracic Oncology, Volume 12, Issue 1, S1197.
  • Christopoulos A, Saif M, Sarris E, Syrigos K. Epidemiology of active tuberculosis in lung cancer patients: a systematic review. Clin Respir J. 2014 Oct;8(4):375-81.
  • Syrigos K, Christopoulos A, Gkiozos I, Charpidou A, Merikas E,Sarris E. Clinical Characteristics and Treatment Response of Active Tuberculosis in Patients with Lung Cancer. Journal of Thoracic Oncology 9(9):S202-S202, September 2014.
  • Gouveris P, Zouki D, Sarris E, et al. Melanoma and Sarcoidosis in Patients Receiving or Not Antineoplastic Therapy. Case Rep Oncol, 2021;14:1059-1065.
  • Ioannou A, Demiri S, Papaxoinis G, Sarris E, et al. Prognostic role of inflammatory biomarkers in patients with advanced pancreatic adenocarcinoma undergoing first-line chemotherapy. Annals of Oncology 3(supp.3):s163, July 2020.
  • Baxevanos P, Gouveris P, Grivas A, Ioannou A, Sarris E, et al. Pneumonitis associated with Paclitaxel Ifosfamide and Cisplatin chemotherapy in a patient with locally advanced penile cancer. FCO Supplementary issue 11 (2) /2020.
  • Ioannou A, Demiri S, Papaxoinis G, Rapti V, Klouva E, Sarris E, et al. Prognostic role white blood cell levels in patients with advanced pancreatic adenocarcinoma undergoing first-line chemotherapy. Annals of Oncology, volume 30, supplement 4, iv80, July 2019.
  • Tryfonopoulos D, Tzouda V, Zouki D, Kyriakidou A, Sarris E, et al. Single center experience with alpelisib-fulvestrant in heavily pretreated women with HR(+), HER-2 (-) metastatic breast cancer. ASCO 2022.
  • Mountzios G, Lampaki S, Linardou H, Georgoulias V, Mavroudis D, Anevlavis S, Charpidou A, Lykka M, Spyratos D, Sarris E, et al. Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the 'EVIDENCE' study. Future Oncol. 2025 Feb;21(4):447-462.
  • Prelaj A, Sacco M, Miskovic V, Lorenzini D, Trovò F, Zec A, Roisman LC, Provenzano L, Proto C, Spagnoletti A, Silvestri C, MeyaA, Pedrocchi A, Sarris E, Felip E, Reck M, De Braud FGM, Lo Russo G, Pearson AT, Garassino MC. Digital pathology predicts PD-L1 expression in metastatic NSCLC patients treated with immunotherapy. Annals of Oncology, Volume 35, S840 - S841, September 2024.
  • Sebri V, Marzorati C, Dorangricchia P, Monzani D, Grasso R, Prelaj A, Provenzano L, Mazzeo L, Dumitrascu AD, Sonnek J, Szewczyk M, Watermann I, Trovò F, Dollis N, Sarris E, et al. The impact of decision tools during oncological consultation with lung cancer patients: A systematic review within the I3LUNG project. Cancer Med. 2024 May;13(9):e7159.
  • SUB-INVESTIGATOR ΣΕ ΠΟΛΥΑΡΙΘΜΕΣ ΔΙΕΘΝΕΙΣ ΚΛΙΝΙΚΕΣ ΜΕΛΕΤΕΣ ΓΙΑ ΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΠΝΕΥΜΟΝΑ, ΟΠΩΣ:
  • INTerpath-009: A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy.
  • ARTEMIA: A Randomised, Open-label, Phase 3 Trial Comparing the Efficacy and Safety of OSE2101 Versus Docetaxel in HLA-A2 Positive Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC) With Secondary Resistance to Immune Checkpoint Inhibitor.
  • TROPION-Lung07: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations.
  • TROPION-Lung08: A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects With Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations.
  • PACIFIC-8: A Phase III, Randomised, Double blind, Placebo controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum based Concurrent Chemoradiation Therapy.
  • MK-3475-U01 (KEYMAKER-U01): Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC).
  • Be6A Lung-02: An Open-label, Randomized, Controlled Phase 3 Study of Sigvotatug Vedotin in Combination with Pembrolizumab Compared with Pembrolizumab Monotherapy as First-line Treatment in Participants with PD-L1 High (≥50% of Tumor Cells Expressing PD-L1), Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer.
  • M18-868: Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer.
  • eVOLVE-01: A Phase II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Volrustomig Priming Regimens in Combination With Other Anticancer Agents in Participants With Solid Tumors.
  • TROPION-Lung15: A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato-DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants With EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Has Progressed on Prior Osimertinib Treatment.

Useful Links

Doctoranytime is an end-to-end solution that assists the user from the moment they experience a health symptom until the moment it is resolved, by enabling them to find the specialist they need, request guidance via chat and talk to them via video call. The information provided has been filled in by Sarris Evangelos and edited by the doctoranytime team.
Log in or register to continue
Are you a new user? Register for free
Log in or register to continue

Continue with

or register with your email address

The password should contain at least 6 characters and 1 capital letter
Are you a registered user?
Create a new password

Enter the email you used to register in doctoranytime and we'll send you a link to create new password

Your data is in good hands
doctor-graphic doctor-graphic

doctoranytime takes your health as well as your data protection very seriously!

In order to ensure you that:

  • you will continue to get the best possible treatment from the affiliated doctors and diagnostic centers
  • you will continue to book your appointments easily and quickly by having at the same time the right of evaluation
  • we will be able to contact you immediately in case of a change in your appointment
  • you will continue to receive our newsletter and health suggestions that may interest you

it is essential for us to collect and process your personal data to the extent that you allow.

For this reason, we would like to inform you that we take all the necessary measures in order to protect your personal data, according to the New European General Data Protection Regulation (“GDPR”), the terms of the doctoranytime Privacy Policy (that you can read in detail here) and the law requirements.

If you have any questions regarding your privacy protection by doctoranytime or in case you wish to exercise your GDPR rights (information, access, correction, deletion, limitation of processing, portability of your data, objection and right to lodge a complaint with the Personal Data Protection Authority) you can contact the Data Protection Officer of doctoranytime on: [email protected].

Terms of Use

Congratulations!!

Your registration has completed.

Check availability
Video Consultation
In-office appointment